CSPC’s CPO301 Receives Third FDA Fast Track Designation

CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.

CSPC Pharmaceutical Group announced that its drug CPO301 has received the third Fast Track designation from the U.S. FDA for treating advanced non-small cell lung cancer (NSCLC) without EGFR mutations. This designation highlights the drug’s promising clinical efficacy and is expected to expedite its development and registration globally, potentially enhancing CSPC’s position in the oncology market.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a company in the pharmaceutical industry, focusing on the development of innovative drugs. It specializes in creating treatments for various diseases, with a significant emphasis on oncology products.

YTD Price Performance: 23.25%

Average Trading Volume: 145,397,173

Technical Sentiment Signal: Buy

Current Market Cap: HK$67.73B

Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.